中华胸心血管外科杂志
中華胸心血管外科雜誌
중화흉심혈관외과잡지
Chinese Journal of Thoracic and Cardiovascular Surgery
2012年
2期
94-98
,共5页
陶运明%胡铁辉%吴忠仕%唐浩%胡野荣%谭琦
陶運明%鬍鐵輝%吳忠仕%唐浩%鬍野榮%譚琦
도운명%호철휘%오충사%당호%호야영%담기
人工血管%肝素%移植,异种%纳米医学%组织相溶性%牛颈静
人工血管%肝素%移植,異種%納米醫學%組織相溶性%牛頸靜
인공혈관%간소%이식,이충%납미의학%조직상용성%우경정
Blood vessel prosthesis%Heparin%Transplantation,hetrologous%Nano medicine%Histocompatibility%Bovine jugular vein
目的 探讨肝素/二羟基铁多层复合物( HDcms)表面纳米修饰对去细胞异种血管生物相容性的影响.方法 采用层层自组装技术将二羟基铁和肝素交替固定在去细胞牛颈静脉(DC-BJV)表面,构建一种新型的抗凝表面,并检测其表面微结构和生物相容性.结果 甲苯胺蓝比色法显示,每组装一次约有(808±86) μg/cm2肝素固定在DC-BJV表面.扫描电镜(SEM)和洗脱试验显示HDcms均匀稳定的包裹在胶原纤维表面,形成纳米膜并持续缓慢地释放肝素.抗凝血活性检测显示,实验组凝血酶原时间(PT)和部分活化凝血酶原时间(APTT)明显高于正常值.血小板黏附实验显示实验组和对照组每10 000 μm2血小板计数分别为(8±4)个和(48±16)个.皮下包埋4周和8周时实验组钙离子含量分别为(8.5±1.9) μg,/mg和(21.5±6.8)μg/mg,对照组钙离子含量分别为(26.6±3.7) μg/mg和(112.6±16.9) μg/mg.结论 HDcms能够牢固地结合在去细胞异种血管表面形成纳米厚度的抗凝表面,并能够提高其生物相容性.
目的 探討肝素/二羥基鐵多層複閤物( HDcms)錶麵納米脩飾對去細胞異種血管生物相容性的影響.方法 採用層層自組裝技術將二羥基鐵和肝素交替固定在去細胞牛頸靜脈(DC-BJV)錶麵,構建一種新型的抗凝錶麵,併檢測其錶麵微結構和生物相容性.結果 甲苯胺藍比色法顯示,每組裝一次約有(808±86) μg/cm2肝素固定在DC-BJV錶麵.掃描電鏡(SEM)和洗脫試驗顯示HDcms均勻穩定的包裹在膠原纖維錶麵,形成納米膜併持續緩慢地釋放肝素.抗凝血活性檢測顯示,實驗組凝血酶原時間(PT)和部分活化凝血酶原時間(APTT)明顯高于正常值.血小闆黏附實驗顯示實驗組和對照組每10 000 μm2血小闆計數分彆為(8±4)箇和(48±16)箇.皮下包埋4週和8週時實驗組鈣離子含量分彆為(8.5±1.9) μg,/mg和(21.5±6.8)μg/mg,對照組鈣離子含量分彆為(26.6±3.7) μg/mg和(112.6±16.9) μg/mg.結論 HDcms能夠牢固地結閤在去細胞異種血管錶麵形成納米厚度的抗凝錶麵,併能夠提高其生物相容性.
목적 탐토간소/이간기철다층복합물( HDcms)표면납미수식대거세포이충혈관생물상용성적영향.방법 채용층층자조장기술장이간기철화간소교체고정재거세포우경정맥(DC-BJV)표면,구건일충신형적항응표면,병검측기표면미결구화생물상용성.결과 갑분알람비색법현시,매조장일차약유(808±86) μg/cm2간소고정재DC-BJV표면.소묘전경(SEM)화세탈시험현시HDcms균균은정적포과재효원섬유표면,형성납미막병지속완만지석방간소.항응혈활성검측현시,실험조응혈매원시간(PT)화부분활화응혈매원시간(APTT)명현고우정상치.혈소판점부실험현시실험조화대조조매10 000 μm2혈소판계수분별위(8±4)개화(48±16)개.피하포매4주화8주시실험조개리자함량분별위(8.5±1.9) μg,/mg화(21.5±6.8)μg/mg,대조조개리자함량분별위(26.6±3.7) μg/mg화(112.6±16.9) μg/mg.결론 HDcms능구뢰고지결합재거세포이충혈관표면형성납미후도적항응표면,병능구제고기생물상용성.
Objective Xenografts have poor biocompatibilities,the aim of this study was to improve the biocompatibilities of decellular xenografts via heparin/dihydroxy-iron complex multilayeres (HDCMs) nanomodification.Methods A novel thrombo-resistant surface for decellular xenograft had been developed by alternating linkage of dihydroxy-iron and heparin to decellular bovine jugular vein (DC-BJV),and surface characterization and biocompatibility of HDCMs nanomodified BJV (HDCMs-BJV) were detected.Results Toluidine blue colorimetric method showed the amount of linked heparin was about (808 ±86) μg/cm2 per assembly-cycle.SEM images proved HDCMs were uniformly linked to and formed nanoscale films around the fibrils of DC-BJV.Washing test proved HDCMs were firmly linked to BJV and sustainedly released heparin for a long time.Tensile test showed that biomechanical stability was increased.Antithrombogenicity test showed that the activated partial thrombin time (APTT) and prothrombin time (PT) of all trial groups were above the normal reference ranges.Platelet adhesion test evaluated mean platelet count per 10 000 μm2 area was 8 ±4 for HDCMs-BJV vs.48 ± 16 for DC-BJV.Endothelial cells (ECs) proliferation test showed the number and activity of ECs on luminal surface of HDCMs-BJV were very similar to DC-BJV at 7-day incubation.Calcium content assay evaluated mean calcium content was ( 8.5 ± 1.9 ) μg/mg dry weight for HDCMs-BJV vs.(26.6 ± 3.7) μg/mg dry weight for DC-BJV at 4 weeks and (21.5 ± 6.8 ) μg/mg dry weight for HDCMsBJV vs.( 112.6 ± 16.9) μg/mg dry weight for DC-BJVs at 8 weeks,respectively.Conclusion These results demonstrate HDCMs were firmly linked to BJV and formed nanoscale thrombo-resistant films,and HDCMs nanomodification improves biocompatibilities of decellular xenograft.